-
公开(公告)号：KR1020150055246A
公开(公告)日：2015-05-21
申请号：KR1020130137333
申请日：2013-11-13
Applicant: 한림대학교 산학협력단
CPC classification number: A61K38/16 , A61K48/00 , Y10S514/886
Abstract: 본발명은빌리버딘환원효소 A에단백질수송도메인이공유결합된 Tat-BLVRA 융합단백질을함유하는피부염증치료제조성물에관한것이다.
Abstract translation: 本发明涉及皮肤炎症的治疗组合物，包括通过共价结合胆红素还原酶A与蛋白质转运结构域而形成的Tat-BLVRA融合蛋白。
-
公开(公告)号：KR1020140140345A
公开(公告)日：2014-12-09
申请号：KR1020130061069
申请日：2013-05-29
Applicant: 한림대학교 산학협력단
CPC classification number: C09D1/00
Abstract: 본 발명은 천연 포졸란을 포함하는 페인트 첨가용 조성물에 관한 것으로서, 더욱 자세하게는 나노 입자의 겔라이트와 천연 미네랄광물이 배합된 천연 포졸란과 천연 흡착제 및 천연 지연제를 혼합한 것으로 염증 억제, 아토피 염증 억제 효능 및 안구질환 예방 등에 탁월한 효과가 있는 페인트 첨가용 조성물에 관한 것이다.
Abstract translation: 本发明涉及添加到油漆中的具有天然火山灰的组合物，更具体地说，涉及添加到具有抑制炎症，特应性皮炎和通过混合天然火山灰，预防眼部疾病的预防眼部疾病的油漆中的天然火山灰的组合物 具有天然缓凝剂的天然吸附剂，其中天然火山灰，天然吸附剂和天然缓凝剂具有纳米颗粒尺寸的凝胶和天然矿物质的混合物。
-
公开(公告)号：KR1020140100021A
公开(公告)日：2014-08-14
申请号：KR1020130012689
申请日：2013-02-05
Applicant: 한림대학교 산학협력단
IPC: A61K31/19 , A61K31/185 , A61K31/353 , A61P35/00
Abstract: The present invention relates to a pharmaceutical composition comprising methyl gallate for preventing and treating tumor. Effects of methyl gallate that affect proliferation and metastasis of glutamate-induced rat C6 and human U373 glioma cells are tested. Cell viability and metastasis are significantly reduced when the glioma cells are treated with the methyl gallate compound of the present invention. The result clearly indicates that the methyl gallate has a strong anti-tumor activity by adjusting Akt and ERK1/2 signal transmission path. Therefore, the methyl gallate can be used as an anti-tumor agent for the glioma cells.
Abstract translation: 本发明涉及包含用于预防和治疗肿瘤的没食子酸甲酯的药物组合物。 测试影响谷氨酸诱导大鼠C6和人U373胶质瘤细胞增殖和转移的没食子酸甲酯的影响。 当用本发明的没食子酸甲酯化合物处理胶质瘤细胞时，细胞活力和转移显着降低。 结果清楚地表明，通过调节Akt和ERK1 / 2信号传递途径，没食子酸甲酯具有很强的抗肿瘤活性。 因此，没食子酸甲酯可用作神经胶质瘤细胞的抗肿瘤剂。
-
公开(公告)号：KR101218067B1
公开(公告)日：2013-01-03
申请号：KR1020090095021
申请日：2009-10-07
Applicant: 한림대학교 산학협력단
Abstract: 본발명은글리옥살레이즈융합단백질및 이를함유하는약제학적조성물에관한것으로서, 활성산소종대사에관여하는글리옥살레이즈를단백질수송도메인과결합시킨융합단백질로제조함으로써세포내로원활히도입시켜뇌허혈등 신경퇴행성질환의예방및 치료제로이용할수 있다.
-
公开(公告)号：KR101214362B1
公开(公告)日：2012-12-21
申请号：KR1020110013166
申请日：2011-02-15
Applicant: 한림대학교 산학협력단
CPC classification number: C12N9/90 , A61K38/00 , A61K38/16 , A61K38/52 , C07K7/06 , C07K14/001 , C07K2319/00 , C07K2319/10 , C12Y502/01008 , Y10S514/914
Abstract: 본발명은안과질환치료제에관한것으로서, 좀더구체적으로는안구조직내투과가가능한 FK506 결합단백질의융합단백질을유효성분으로함유하는안과질환치료용약제학적조성물에관한것이다.
-
Patent Agency Ranking
公开(公告)号：KR101176793B1
公开(公告)日：2012-09-07
申请号：KR1020100103874
申请日：2010-10-25
Applicant: 한림대학교 산학협력단 , 대한민국(농촌진흥청장)
Abstract: 본 발명은 척추압박골절에 대한 척추성형술 등의 용도로 사용되는 생체적합성 골 시멘트 조성물에 관한 것으로서, 가수분해된 실크 피브로인 분말, 아크릴계 고분자, 중합개시제가 함유된 분말부분과, 아크릴 단량체, 중합촉진제, 중합금지제가 함유된 액체부분으로 구성되어 실크 피브로인 가수분해물 제조방법이나 제조된 실크 피브로인 가수분해물과 아크릴계 고분자 및 단량체의 혼합비율에 따라 골절 척추체 주입용 골 시멘트로써의 적정강도와 생체적합성을 갖추고 더 나아가 실크 피브로인 가수분해물에 따라 골형성을 촉진할 수 있다는 것을 요지로 한다.
-
67.发明公开소목, 희첨 및 세포침투성 ＨＳＰ27 융합단백질을 포함하는 항염증 피부외용제 조성물 有权含有CAESAPINIA SAPPAN，SIEGESBECKIA GLABRESCENS MAKINO和细胞转导热休克蛋白的抗炎性皮肤组合物27融合蛋白
公开(公告)号：KR1020110136518A
公开(公告)日：2011-12-21
申请号：KR1020100056593
申请日：2010-06-15
Applicant: 한림대학교 산학협력단 , 주식회사 바이피엘
CPC classification number: A61K36/48 , A61K8/97 , A61K36/28 , Y10S514/844 , Y10S514/857
Abstract: PURPOSE: An external use skin composition containing Caesapinia sappan L. extract and cell permeable HSP27 fusion protein is provided to suppress edema and to ensure anti-inflammation. CONSTITUTION: An external use composition for anti-inflammation contains each 0.001-50 wt% of Caesapinia sappan L. extract, Siegesbeckia glabrescens Makino extract, and cell permeable HSP27 fusion protein. The cell permeable HSP27 fusion protein is Pep-HSP27 fusion protein. The external use skin composition is manufactured in the form of a lotion, gel, water soluble liquid, cream, essence, and water-in-oil type or oil-in-water formulation. The composition is a pharmaceutical or cosmetic composition.
Abstract translation: 目的：提供含有辣椒碱提取物和细胞渗透性HSP27融合蛋白的外用皮肤组合物，以抑制水肿并确保抗炎。 构成：用于抗炎的外用组合物含有Caesapinia sappan L.提取物，Siegesbeckia glabrescens Makino提取物和细胞渗透性HSP27融合蛋白的0.001-50重量％。 细胞渗透性HSP27融合蛋白是Pep-HSP27融合蛋白。 外用皮肤组合物以洗剂，凝胶，水溶性液体，霜剂，精华油和油包水型或水包油制剂的形式制造。 组合物是药物或化妆品组合物。
-
68.发明公开희첨 및 세포침투성 ＨＳＰ27 융합단백질을 포함하는 항염증 피부외용제 조성물 无效含有SIEGESBECKIA GLABRESCENS MAKINO和细胞转导热休克蛋白27抗融合蛋白的抗炎性皮肤组合物
公开(公告)号：KR1020110136372A
公开(公告)日：2011-12-21
申请号：KR1020100056324
申请日：2010-06-15
Applicant: 한림대학교 산학협력단
Abstract: PURPOSE: An external use composition containing Siegesbeckia glabrescens Makino extract and cell permeable HSP27 fusion protein is provided to effectively treat atopic dermatitis and acne. CONSTITUTION: An external use composition for anti-inflammation contains 0.001-50 wt% of Siegesbeckia glabrescens Makino extract and cell permeable HSP27 fusion protein. The composition is a pharmaceutical composition or cosmetic composition. The composition is manufactured in the form of a tonic, lotion, emulsion, cream, ointment, gel, spray, mousse, capsule, or plaster. The daily dose of the composition is 0.0001-100 mg/kg.
Abstract translation: 目的：提供含有Siegesbeckia glabrescens Makino提取物和细胞渗透性HSP27融合蛋白的外用组合物，有效治疗特应性皮炎和痤疮。 构成：用于抗炎的外用组合物含有0.001-50wt％的Siegesbeckia glabrescens Makino提取物和细胞可渗透的HSP27融合蛋白。 该组合物是药物组合物或化妆品组合物。 组合物以补品，洗剂，乳剂，霜剂，软膏，凝胶，喷雾剂，摩丝，胶囊或石膏的形式制备。 组合物的日剂量为0.0001-100mg / kg。
-
公开(公告)号：KR1020110122049A
公开(公告)日：2011-11-09
申请号：KR1020100103874
申请日：2010-10-25
Applicant: 한림대학교 산학협력단 , 대한민국(농촌진흥청장)
CPC classification number: A61L24/043 , A61F2/28 , A61L24/106
Abstract: PURPOSE: A bone cement composition is provided to secure biocompatible stiffness instead of overly high stiffness. CONSTITUTION: A bone cement composition includes: a powder part containing silk fibroin hydrolysate powder, polyacrylo-nitrile PMMA, and polymerization initiator; and a fluid part containing acrylic monomer, polymerization accelerator, and polymer inhibitor. The powder part and fluid part are mixed with each other. The silk fibroin hydrolysate powder has molecular weight 0.1-100 kDa.
Abstract translation: 目的：提供骨水泥组合物以确保生物相容的刚度而不是过高的刚度。 构成：骨水泥组合物包括：含有丝素蛋白水解物粉末，聚丙烯腈PMMA和聚合引发剂的粉末部分; 和含有丙烯酸单体，聚合促进剂和聚合物抑制剂的流体部分。 粉末部分和流体部分彼此混合。 丝素蛋白水解物粉末的分子量为0.1-100kDa。
-
公开(公告)号：KR1020110061668A
公开(公告)日：2011-06-10
申请号：KR1020090118135
申请日：2009-12-02
Applicant: 한림대학교 산학협력단 , 대한민국(농촌진흥청장)
Abstract: PURPOSE: An AMP-activated protein kinase fusion protein is provided to suppress inflammation by intracellular concentration-dependent and time-dependent introduction. CONSTITUTION: A cell permeable AMP-activated protein kinase fusion protein has a protein transport domain which is bound to at least one terminal of the AMP-activated protein kinase. The protein transport domain is PEP-1 peptide. The AMP-activated protein kinase has an amino acid of sequence number 7. A cosmetic composition contains the AMP-activated protein kinase as an active ingredient. A pharmaceutical composition for treating inflammation including type 2 diabetes, obesity, skin cancer, and atopic inflammation contains the AMP-activated protein kinase as an active ingredient and pharmaceutically acceptable carrier.
Abstract translation: 目的：提供AMP激活的蛋白激酶融合蛋白，以通过细胞内浓度依赖性和时间依赖性介导来抑制炎症。 构成：细胞可渗透的AMP激活蛋白激酶融合蛋白具有蛋白转运结构域，其结合AMP活化蛋白激酶的至少一个末端。 蛋白质转运结构域是PEP-1肽。 AMP活化蛋白激酶具有序列号7的氨基酸。化妆品组合物含有AMP活化蛋白激酶作为活性成分。 用于治疗包括2型糖尿病，肥胖症，皮肤癌和特应性炎症的炎症的药物组合物含有AMP活化蛋白激酶作为活性成分和药学上可接受的载体。
-
-
-
-
-
-
-
-
-
Search Results
99
records
(took 0.03 seconds)
